List view / Grid view
27 June 2016 | By Victoria White, Digital Content Producer
Merck’s acquisition of Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing IPF market, according to GlobalData...
27 June 2016 | By Victoria White, Digital Content Producer
While a Brexit undoubtedly creates significant issues for the UK pharma industry, opportunities remain for the sector to thrive, according to GlobalData...
23 June 2016 | By Victoria White, Digital Content Producer
The company says for the healthcare industry to thrive in the event of the UK leaving the EU, the country would need to adopt a uniquely British approach...
22 June 2016 | By Victoria White, Digital Content Producer
The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData...
21 June 2016 | By Victoria White, Digital Content Producer
The idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, according to GlobalData...
16 June 2016 | By Victoria White, Digital Content Producer
New data on IMAB362 provides hope for a subset of gastric and gastroesophageal junction adenocarcinoma patients, according to GlobalData...
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
7 June 2016 | By Victoria White, Digital Content Producer
The meningococcal vaccines market is expected to grow from around $1.1 billion in 2015 to $1.8 billion by 2025, according to GlobalData...
1 June 2016 | By Victoria White, Digital Content Producer
New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
25 May 2016 | By Victoria White, Digital Content Producer
ChemoCentryx’s CCX168 has strong potential to address major unmet needs in the vasculitis space, according to an analyst with GlobalData...
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
19 April 2016 | By Victoria White, Digital Content Producer
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, according to GlobalData...
The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
